Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 14(1): 3188, 2023 06 06.
Article in English | MEDLINE | ID: mdl-37280206

ABSTRACT

The success of cancer immunotherapy depends in part on the strength of antigen recognition by T cells. Here, we characterize the T cell receptor (TCR) functional (antigen sensitivity) and structural (monomeric pMHC-TCR off-rates) avidities of 371 CD8 T cell clones specific for neoantigens, tumor-associated antigens (TAAs) or viral antigens isolated from tumors or blood of patients and healthy donors. T cells from tumors exhibit stronger functional and structural avidity than their blood counterparts. Relative to TAA, neoantigen-specific T cells are of higher structural avidity and, consistently, are preferentially detected in tumors. Effective tumor infiltration in mice models is associated with high structural avidity and CXCR3 expression. Based on TCR biophysicochemical properties, we derive and apply an in silico model predicting TCR structural avidity and validate the enrichment in high avidity T cells in patients' tumors. These observations indicate a direct relationship between neoantigen recognition, T cell functionality and tumor infiltration. These results delineate a rational approach to identify potent T cells for personalized cancer immunotherapy.


Subject(s)
Melanoma , Animals , Mice , Melanoma/metabolism , CD8-Positive T-Lymphocytes , Receptors, Antigen, T-Cell/metabolism , Antigens, Neoplasm , Clone Cells/metabolism
2.
Nat Biotechnol ; 40(5): 656-660, 2022 05.
Article in English | MEDLINE | ID: mdl-34782741

ABSTRACT

The identification of patient-specific tumor antigens is complicated by the low frequency of T cells specific for each tumor antigen. Here we describe NeoScreen, a method that enables the sensitive identification of rare tumor (neo)antigens and of cognate T cell receptors (TCRs) expressed by tumor-infiltrating lymphocytes. T cells transduced with tumor antigen-specific TCRs identified by NeoScreen mediate regression of established tumors in patient-derived xenograft mice.


Subject(s)
Neoplasms , Receptors, Antigen, T-Cell , Animals , Antigens, Neoplasm/genetics , CD8-Positive T-Lymphocytes , Humans , Lymphocytes, Tumor-Infiltrating , Mice , Neoplasms/genetics , Neoplasms/therapy , Receptors, Antigen, T-Cell/genetics , T-Lymphocytes
3.
Cell Rep Med ; 2(2): 100194, 2021 02 16.
Article in English | MEDLINE | ID: mdl-33665637

ABSTRACT

CD8+ T cell recognition of peptide epitopes plays a central role in immune responses against pathogens and tumors. However, the rules that govern which peptides are truly recognized by existing T cell receptors (TCRs) remain poorly understood, precluding accurate predictions of neo-epitopes for cancer immunotherapy. Here, we capitalize on recent (neo-)epitope data to train a predictor of immunogenic epitopes (PRIME), which captures molecular properties of both antigen presentation and TCR recognition. PRIME not only improves prioritization of neo-epitopes but also correlates with T cell potency and unravels biophysical determinants of TCR recognition that we experimentally validate. Analysis of cancer genomics data reveals that recurrent mutations tend to be less frequent in patients where they are predicted to be immunogenic, providing further evidence for immunoediting in human cancer. PRIME will facilitate identification of pathogen epitopes in infectious diseases and neo-epitopes in cancer immunotherapy.


Subject(s)
Antigen Presentation/immunology , Epitopes, T-Lymphocyte/immunology , Neoplasms/immunology , Receptors, Antigen, T-Cell/immunology , CD8-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/genetics , Humans , Immunotherapy/methods , Peptides/immunology
4.
Methods Enzymol ; 631: 21-42, 2020.
Article in English | MEDLINE | ID: mdl-31948548

ABSTRACT

Peptide major histocompatibility complex (pMHC) multimers have been used since decades to identify, isolate and analyze antigen-specific T cells by flow (and more recently mass) cytometry. Yet well established as a standard technology, improvements are still required to face the growing needs of personalized immune monitoring. Here we review the latest developments about (i) the quality of pMHC class I and II monomers, (ii) the importance of the multimeric scaffold, (iii) the staining conditions and (iv) the high-throughput synthesis of pMHC monomers. Finally, innovative multiplexed, combinatorial strategies for parallel detection of antigen-specific T cells in a single sample are discussed.


Subject(s)
CD4-Positive T-Lymphocytes , CD8-Positive T-Lymphocytes , Flow Cytometry/methods , Immunologic Techniques/methods , Humans , Major Histocompatibility Complex , Peptides , Staining and Labeling
SELECTION OF CITATIONS
SEARCH DETAIL
...